|Articles|March 1, 2004

Illuminating therapies

Washington, D.C. - Ongoing work regarding aminolevulinic acid (ALA) for photodynamic therapy provides a shining example of the value of off-label uses. The drug has earned UK approval for treating skin cancer and FDA approval for actinic keratoses. However, its most effective applications may well be cosmetic treatments including photo-rejuvenation, acne, and sebaceous gland hyperplasia.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME